

# Anders Bjartell

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5153557/anders-bjartell-publications-by-year.pdf>

**Version:** 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

267  
papers

9,637  
citations

53  
h-index

89  
g-index

294  
ext. papers

11,497  
ext. citations

5.6  
avg, IF

5.79  
L-index

#	Paper	IF	Citations
267	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , <b>2022</b> ,	10.2	2
266	The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 89-89	2.2	
265	Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer.. <i>European Urology</i> , <b>2022</b> ,	10.2	
264	Nuclear expression of pSTAT3 and pSTAT3 in the stromal compartment of localized hormone-naïve prostate cancer.. <i>Pathology Research and Practice</i> , <b>2022</b> , 232, 153811	3.4	0
263	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review.. <i>BMJ Open</i> , <b>2022</b> , 12, e058267	3	0
262	Freely available artificial intelligence for pelvic lymph node metastases in PSMA PET-CT that performs on par with nuclear medicine physicians.. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2022</b> , 1	8.8	0
261	Learning curve for robot-assisted laparoscopic radical prostatectomy in a large prospective multicentre study.. <i>Scandinavian Journal of Urology</i> , <b>2022</b> , 1-9	1.6	
260	A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.. <i>European Urology</i> , <b>2021</b> ,	10.2	14
259	Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiongß Letter to the Editor re: Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. <i>Eur Urol</i> <b>2021</b> ;69:150-59. <i>European Urology</i> , <b>2021</b> , 81, 19-19	10.2	
258	An Artificial Intelligence-based Support Tool for Automation and Standardisation of Gleason Grading in Prostate Biopsies. <i>European Urology Focus</i> , <b>2021</b> , 7, 995-1001	5.1	4
257	COVIDENZA - A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID-19): a structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2021</b> , 22, 209	2.8	7
256	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. <i>EBioMedicine</i> , <b>2021</b> , 65, 103269	8.8	8
255	Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 3155-3166	7.4	3
254	Urinary continence recovery and oncological outcomes after surgery for prostate cancer analysed by risk category: results from the LAParoscopic prostatectomy robot and open trial. <i>World Journal of Urology</i> , <b>2021</b> , 39, 3239-3249	4	2
253	A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned. <i>Journal of Urology</i> , <b>2021</b> , 205, 1145-1152	2.5	
252	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. <i>Targeted Oncology</i> , <b>2021</b> , 16, 357-367	5	2
251	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , <b>2021</b> , 15, e2000025	3.1	1

250	Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 5068-5077	2.2	0
249	A retrospective study assessing the accuracy of [18F]-fluorocholine PET/CT for primary staging of lymph node metastases in intermediate and high-risk prostate cancer patients undergoing robotic-assisted laparoscopic prostatectomy with extended lymph node dissection. <i>Scandinavian Journal of Urology</i> , <b>2021</b> , 55, 293-297	1.6	0
248	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , <b>2021</b> , 127, 96-107	5.6	3
247	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 469-476	8.8	42
246	The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development. <i>Pharmacoeconomics - Open</i> , <b>2021</b> , 5, 77-88	2.1	2
245	Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial. <i>BJU International</i> , <b>2021</b> , 127, 361-368	5.6	9
244	IMAGINE-IMPact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. <i>European Urology</i> , <b>2021</b> , 79, 173-176	10.2	4
243	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. <i>European Urology Oncology</i> , <b>2021</b> , 4, 49-55	6.7	5
242	Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. <i>European Urology Focus</i> , <b>2021</b> , 7, 178-185	5.1	2
241	Vesicourethral Anastomotic Stenosis After Open or Robot-assisted Laparoscopic Retropubic Prostatectomy-Results from the Laparoscopic Prostatectomy Robot Open Trial. <i>European Urology Focus</i> , <b>2021</b> , 7, 317-324	5.1	6
240	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
239	Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. <i>European Urology Focus</i> , <b>2021</b> ,	5.1	1
238	Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 11-11	2.2	0
237	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <i>Journal of Pathology: Clinical Research</i> , <b>2021</b> , 7, 311-325	5.3	6
236	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e040531	3	1
235	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2294-2303	2.2	27
234	Degree of Preservation of Neurovascular Bundles in Radical Prostatectomy and Recurrence of Prostate Cancer. <i>European Urology Open Science</i> , <b>2021</b> , 30, 25-33	0.9	2
233	Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [F]DCFPyL (PSMA) imaging for standardized reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 1	8.8	3

232	Quantification of microRNA editing using two-tailed RT-qPCR for improved biomarker discovery. <i>Rna</i> , <b>2021</b> , 27, 1412-1424	5.8	1
231	Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. <i>European Urology</i> , <b>2021</b> , 80, 650-660	10.2	12
230	Reply by Authors. <i>Journal of Urology</i> , <b>2021</b> , 206, 923	2.5	
229	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. <i>European Urology Focus</i> , <b>2021</b> , 7, 943-946	5.1	0
228	Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. <i>Journal of Urology</i> , <b>2021</b> , 206, 914-923	2.5	2
227	Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. <i>Biomedicine Hub</i> , <b>2020</b> , 5, 182-223	1.3	6
226	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , <b>2020</b> , 17, 351-362	5.5	7
225	Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. <i>Targeted Oncology</i> , <b>2020</b> , 15, 301-315	5	17
224	Cytokines and Janus kinase/signal transducer and activator of transcription signaling in prostate cancer: overview and therapeutic opportunities. <i>Current Opinion in Endocrine and Metabolic Research</i> , <b>2020</b> , 10, 36-42	1.7	5
223	Re: 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort. <i>European Urology</i> , <b>2020</b> , 78, 632	10.2	1
222	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , <b>2020</b> , 77, 508-547	10.2	155
221	Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 82-82	2.2	3
220	Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with low- and high-risk disease.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 87-87	2.2	1
219	A nutrient-wide association study for risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition and the Netherlands Cohort Study. <i>European Journal of Nutrition</i> , <b>2020</b> , 59, 2929-2937	5.2	6
218	Hospital readmissions after limited vs. extended lymph node dissection during open and robot-assisted radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 5.e1-5.e8	2.8	1
217	Scavenging of Labile Heme by Hemopexin Is a Key Checkpoint in Cancer Growth and Metastases. <i>Cell Reports</i> , <b>2020</b> , 32, 108181	10.6	11
216	Do negative intrusive thoughts at diagnosis predict impaired quality of life, depressed mood and waking up with anxiety 3, 12 and 24 months after radical prostatectomy? - a longitudinal study. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 220-226	1.6	1
215	Risk of Recurrent Disease 6 Years After Open or Robotic-assisted Radical Prostatectomy in the Prospective Controlled Trial LAPPRO. <i>European Urology Open Science</i> , <b>2020</b> , 20, 54-61	0.9	2

214	STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. <i>Scientific Reports</i> , <b>2020</b> , 10, 13958	4.9	8
213	Intake of individual fatty acids and risk of prostate cancer in the European prospective investigation into cancer and nutrition. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 44-57	7.5	7
212	Associations between intraoperative factors and surgeons' self-assessed operative satisfaction. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2020</b> , 34, 61-68	5.2	2
211	Assessing Radiographic Response to Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , 61, 671-675	8.9	6
210	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , <b>2020</b> , 3, 80-91	6.7	11
209	Update on a real-world study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Scandinavian Journal of Urology</i> , <b>2020</b> , 54, 263-264	1.6	
208	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , <b>2019</b> , 76, 693-702	10.2	12
207	The $\beta$ -Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 2154-2168	6.6	16
206	A registry-based study evaluating overall survival and treatment duration in Swedish patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Scandinavian Journal of Urology</i> , <b>2019</b> , 53, 312-318	1.6	4
205	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 13-24	59.2	450
204	Agreement between patient reported outcomes and clinical reports after radical prostatectomy - a prospective longitudinal study. <i>BMC Urology</i> , <b>2019</b> , 19, 35	2.2	3
203	New Hope in Prostate Cancer Precision Medicine? miRNA Replacement and Epigenetics. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2679-2681	12.9	5
202	Expression of tSTAT3, pSTAT3, and pSTAT3 in the epithelial cells of hormone-naïve prostate cancer. <i>Prostate</i> , <b>2019</b> , 79, 784-797	4.2	6
201	The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors. <i>Prostate</i> , <b>2019</b> , 79, 1611-1621	4.2	33
200	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , <b>2019</b> , 76, 790-813	10.2	76
199	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , <b>2019</b> , 20, 1518-1530	21.7	32
198	First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 5006-5006	2.2	2
197	90-Day readmission after radical prostatectomy-a prospective comparison between robot-assisted and open surgery. <i>Scandinavian Journal of Urology</i> , <b>2019</b> , 53, 26-33	1.6	15

196	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , <b>2019</b> , 2, 333-336	6.7	4
195	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , <b>2019</b> , 75, 523-531	10.2	33
194	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 595-608	12.9	29
193	Quality of Life After Open Radical Prostatectomy Compared with Robot-assisted Radical Prostatectomy. <i>European Urology Focus</i> , <b>2019</b> , 5, 389-398	5.1	18
192	Role of serum response factor expression in prostate cancer biochemical recurrence. <i>Prostate</i> , <b>2018</b> , 78, 724-730	4.2	5
191	A prospective study to evaluate the intra-individual reproducibility of bone scans for quantitative assessment in patients with metastatic prostate cancer. <i>BMC Medical Imaging</i> , <b>2018</b> , 18, 8	2.9	1
190	Plasma enterolactone and risk of prostate cancer in middle-aged Swedish men. <i>European Journal of Nutrition</i> , <b>2018</b> , 57, 2595-2606	5.2	8
189	Social constraints and psychological well-being after prostate cancer: A follow-up at 12 and 24 months after surgery. <i>Psycho-Oncology</i> , <b>2018</b> , 27, 668-675	3.9	7
188	Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial. <i>European Urology</i> , <b>2018</b> , 73, 618-627	10.2	50
187	Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial. <i>European Urology</i> , <b>2018</b> , 74, 816-824	10.2	37
186	<b>2018</b> ,		15
185	ProBio II: An adaptive and randomized multi-arm biomarker driven phase 2 study in men with castrate resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS397-TPS397	2.2	1
184	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 944-951	13.4	50
183	Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial. <i>European Urology Oncology</i> , <b>2018</b> , 1, 353-360	6.7	35
182	Expression of STAT3 in Prostate Cancer Metastases. <i>European Urology</i> , <b>2017</b> , 71, 313-316	10.2	57
181	Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele. <i>Cancer Causes and Control</i> , <b>2017</b> , 28, 227-233	2.8	
180	Habits and self-assessed quality of life, negative intrusive thoughts and depressed mood in patients with prostate cancer: a longitudinal study. <i>Scandinavian Journal of Urology</i> , <b>2017</b> , 51, 353-359	1.6	9
179	Corrigendum re: "Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial" [Eur Urol 2015;68:216-25]. <i>European Urology</i> , <b>2017</b> , 72, e81-e82	10.2	3



178	Type 2 diabetes, adiposity and cancer morbidity and mortality risk taking into account competing risk of noncancer deaths in a prospective cohort setting. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 1170-1180	7.5	13
177	Automatic Gleason grading of H and E stained microscopic prostate images using deep convolutional neural networks <b>2017</b> ,		3
176	Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. <i>Prostate</i> , <b>2017</b> , 77, 849-858	4.2	23
175	How badly did it hit? Self-assessed emotional shock upon prostate cancer diagnosis and psychological well-being: a follow-up at 3, 12, and 24 months after surgery. <i>Acta Oncologica</i> , <b>2017</b> , 56, 984-990	3.2	4
174	Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation. <i>Therapeutic Advances in Urology</i> , <b>2017</b> , 9, 127-136	3.2	4
173	Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184418	3.7	44
172	Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing. <i>Progress in Preventive Medicine (New York, N Y)</i> , <b>2017</b> , 2, e006	0.7	5
171	Identification of a Novel Autoimmune Peptide Epitope of Prostein in Prostate Cancer. <i>Journal of Proteome Research</i> , <b>2017</b> , 16, 204-216	5.6	14
170	Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. <i>Biomedicine Hub</i> , <b>2017</b> , 2, 162-168	1.3	0
169	Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 170-170	2.2	2
168	Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 212-212	2.2	2
167	The prognostic impact of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 47-47	2.2	1
166	Cartilage oligomeric matrix protein promotes prostate cancer progression by enhancing invasion and disrupting intracellular calcium homeostasis. <i>Oncotarget</i> , <b>2017</b> , 8, 98298-98311	3.3	23
165	Prognostic significance of professional antigen presenting cells according to morphological subtype of periampullary adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 121-121	2.2	
164	The prognostic impact of CD3, CD8, FoxP3, and IL17 tumor-infiltrating immune cells in periampullary cancer differs by morphological type and adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 53-53	2.2	
163	Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 5028-5028	2.2	1
162	Treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) and cardiovascular disorders or diabetes: The Prostate Cancer Registry.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e16537-e16537	2.2	
161	The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 69, 400-4	10.2	35

160	A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 1865-1871	8.9	22
159	Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. <i>European Urology Focus</i> , <b>2016</b> , 2, 547-552	5.1	12
158	Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate. <i>BMC Urology</i> , <b>2016</b> , 16, 10	2.2	12
157	Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. <i>EJNMMI Research</i> , <b>2016</b> , 6, 23	3.6	28
156	The Proteome of Primary Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 69, 942-52	10.2	97
155	Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities. <i>Seminars in Nuclear Medicine</i> , <b>2016</b> , 46, 165-79	5.4	18
154	Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , <b>2016</b> , 57, 41-5	8.9	39
153	Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155901	3.7	30
152	The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156497	3.7	16
151	Expression of the TP $\alpha$ and TP $\beta$ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential. <i>Oncotarget</i> , <b>2016</b> , 7, 73171-73187	3.3	6
150	Low $\beta$ adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. <i>Oncotarget</i> , <b>2016</b> , 7, 1878-94	3.3	8
149	Automated bone scan index as a quantitative imaging biomarker indicative of efficacy to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 226-226	2.2	
148	Automated bone scan index as an imaging biomarker in metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16600-e16600 <sup>2,2</sup>	2.2	
147	Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e16599-e16599	2.2	
146	The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5024-5024 <sup>2,3</sup>	2.2	
145	PBX3 is a putative biomarker of aggressive prostate cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 139, 1810-20	7.5	30
144	Oncological and functional outcomes 1 year after radical prostatectomy for very-low-risk prostate cancer: results from the prospective LAPPRO trial. <i>BJU International</i> , <b>2016</b> , 118, 205-12	5.6	23
143	Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO. <i>Acta Oncologica</i> , <b>2016</b> , 55, 1467-1476	3.2	7



142	The Molecular Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , <b>2016</b> , 2, 506-513	5.1	23
141	Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2016</b> , 64, 311-22	3.4	
140	Psychological Well-being and Private and Professional Psychosocial Support After Prostate Cancer Surgery: A Follow-up at 3, 12, and 24 Months After Surgery. <i>European Urology Focus</i> , <b>2016</b> , 2, 418-425	5.1	11
139	Prediction of clinical progression after radical prostatectomy in a nationwide population-based cohort. <i>Scandinavian Journal of Urology</i> , <b>2016</b> , 50, 255-9	1.6	5
138	Accurate prediction tools in prostate cancer require consistent assessment of included variables. <i>Scandinavian Journal of Urology</i> , <b>2016</b> , 50, 260-6	1.6	3
137	Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. <i>European Urology Focus</i> , <b>2016</b> , 2, 540-546	5.1	21
136	Preclinical Characterization of 3E(N-Acetyl l-cysteine methyl ester)-2aβ-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 4551-62	8.3	21
135	Re: The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. <i>European Urology</i> , <b>2016</b> , 70, 700	10.2	1
134	miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. <i>Carcinogenesis</i> , <b>2015</b> , 36, 858-66	4.6	46
133	Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. <i>European Urology</i> , <b>2015</b> , 68, 216-25	10.2	252
132	Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. <i>Nuclear Medicine and Biology</i> , <b>2015</b> , 42, 375-80	2.1	6
131	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. <i>European Urology</i> , <b>2015</b> , 68, 1076-82	10.2	11
130	Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. <i>World Journal of Urology</i> , <b>2015</b> , 33, 907-16	4	9
129	Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. <i>European Urology</i> , <b>2015</b> , 67, 660-70	10.2	69
128	Thromboembolic complications in 3,544 patients undergoing radical prostatectomy with or without lymph node dissection. <i>Journal of Urology</i> , <b>2015</b> , 193, 117-25	2.5	44
127	Relationship between serum response factor and androgen receptor in prostate cancer. <i>Prostate</i> , <b>2015</b> , 75, 1704-17	4.2	5
126	Analysis of the Human Prostate-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling Identifies TMEM79 and ACOXL as Two Putative, Diagnostic Markers in Prostate Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133449	3.7	17
125	miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen. <i>European Urology</i> , <b>2015</b> , 68, 581-8	10.2	30

124	Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. <i>European Urology</i> , <b>2015</b> , 67, 349-50	10.2	1
123	Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. <i>European Urology</i> , <b>2015</b> , 67, 348-9	10.2	
122	Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. <i>European Urology</i> , <b>2015</b> , 67, 559-68	10.2	76
121	Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5044-5044	2.2	
120	TCF7L2 type 2 diabetes risk variant, lifestyle factors, and incidence of prostate cancer. <i>Prostate</i> , <b>2014</b> , 74, 1161-70	4.2	5
119	Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 15969-78	5.4	70
118	The fungal metabolite galiellalactone interferes with the nuclear import of NF- $\kappa$ B and inhibits HIV-1 replication. <i>Chemico-Biological Interactions</i> , <b>2014</b> , 214, 69-76	5	11
117	Analysis of plasma from prostate cancer patients links decreased carnosine dipeptidase 1 levels to lymph node metastasis. <i>Translational Proteomics</i> , <b>2014</b> , 2, 14-24		8
116	Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens. <i>Urology</i> , <b>2014</b> , 83, 511.e1-7	1.6	15
115	Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2048-56	4	7
114	Interobserver variability in the pathological assessment of radical prostatectomy specimens: findings of the Laparoscopic Prostatectomy Robot Open (LAPPRO) study. <i>Scandinavian Journal of Urology</i> , <b>2014</b> , 48, 160-7	1.6	15
113	Burden of Illness in Prostate Cancer Patients with a Low-to-Moderate Risk of Progression: A One-Year, Pan-European Observational Study. <i>Prostate Cancer</i> , <b>2014</b> , 2014, 472949	1.9	13
112	Identification of plasma protein profiles associated with risk groups of prostate cancer patients. <i>Proteomics - Clinical Applications</i> , <b>2014</b> , 8, 951-62	3.1	9
111	Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy. <i>EJNMMI Research</i> , <b>2014</b> , 4, 58	3.6	26
110	Plasma alkylresorcinol metabolites as biomarkers for whole-grain intake and their association with prostate cancer: a Swedish nested case-control study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 73-83	4	17
109	Preclinical evaluation of (111)In-DTPA-INCA-X anti-Ku70/Ku80 monoclonal antibody in prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2014</b> , 4, 311-23	2.2	
108	Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 244-244	2.2	
107	Low expression of SHP-2 is associated with less favorable prostate cancer outcomes. <i>Tumor Biology</i> , <b>2013</b> , 34, 637-42	2.9	11

106	The mutational landscape of prostate cancer. <i>European Urology</i> , <b>2013</b> , 64, 567-76	10.2	144
105	Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. <i>European Urology</i> , <b>2013</b> , 63, 597-603	10.2	365
104	Automatic registration of multi-modal microscopy images for integrative analysis of prostate tissue sections. <i>BMC Cancer</i> , <b>2013</b> , 13, 408	4.8	15
103	A systematic review of the volume-outcome relationship for radical prostatectomy. <i>European Urology</i> , <b>2013</b> , 64, 786-98	10.2	136
102	miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 2867-75	7.5	65
101	Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. <i>Cancer Research</i> , <b>2013</b> , 73, 7009-21	10.1	210
100	High expression of midkine in the airways of patients with cystic fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2013</b> , 49, 935-42	5.7	16
99	Midkine is part of the antibacterial activity released at the surface of differentiated bronchial epithelial cells. <i>Journal of Innate Immunity</i> , <b>2013</b> , 5, 519-30	6.9	12
98	Copy number variants in the kallikrein gene cluster. <i>PLoS ONE</i> , <b>2013</b> , 8, e69097	3.7	2
97	Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. <i>PLoS ONE</i> , <b>2013</b> , 8, e72400	3.7	62
96	Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. <i>European Urology</i> , <b>2012</b> , 61, 471-7	10.2	41
95	A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. <i>European Urology</i> , <b>2012</b> , 62, 78-84	10.2	123
94	A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens. <i>European Urology</i> , <b>2012</b> , 62, 20-39	10.2	70
93	Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. <i>World Journal of Urology</i> , <b>2012</b> , 30, 785-94	4	9
92	A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 985-93	8.9	25
91	Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2012</b> , 27, 243-51	3.9	10
90	Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer. <i>Cancer Medicine</i> , <b>2012</b> , 1, 96-104	4.8	16
89	Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the MalmDiet and Cancer cohort. <i>American Journal of Clinical Nutrition</i> , <b>2012</b> , 96, 1409-18	7	65

88	β-syntrophin and Par-3 promote an apicobasal Rac activity gradient at cell-cell junctions by differentially regulating Tiam1 activity. <i>Nature Cell Biology</i> , <b>2012</b> , 14, 1169-80	23.4	40
87	Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. <i>Journal of Leukocyte Biology</i> , <b>2011</b> , 89, 177-87	6.5	51
86	Tumor markers in prostate cancer I: blood-based markers. <i>Acta Oncologica</i> , <b>2011</b> , 50 Suppl 1, 61-75	3.2	133
85	Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2011</b> , 29, 436-45	2.8	38
84	Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. <i>PLoS ONE</i> , <b>2011</b> , 6, e26539	3.7	43
83	SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. <i>American Journal of Surgical Pathology</i> , <b>2011</b> , 35, 937-48	6.7	183
82	Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. <i>PLoS ONE</i> , <b>2011</b> , 6, e22118	3.7	74
81	Multicomponent <i>Moraxella catarrhalis</i> outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells. <i>Cellular Microbiology</i> , <b>2011</b> , 13, 432-49	3.9	86
80	High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. <i>Diagnostic Pathology</i> , <b>2011</b> , 6, 91	3	34
79	Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. <i>European Urology</i> , <b>2011</b> , 59, 962-77	10.2	198
78	Epigenetics in prostate cancer: biologic and clinical relevance. <i>European Urology</i> , <b>2011</b> , 60, 753-66	10.2	164
77	Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. <i>European Urology</i> , <b>2011</b> , 60, 1045-54	10.2	119
76	Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. <i>Acta Oncologica</i> , <b>2011</b> , 50 Suppl 1, 76-84	3.2	46
75	Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. <i>Modern Pathology</i> , <b>2011</b> , 24, 708-19	9.8	27
74	A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2011</b> , 20, 255-61	4	70
73	Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. <i>Cancer Research</i> , <b>2011</b> , 71, 1956-67	10.1	206
72	Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. <i>Molecular and Cellular Proteomics</i> , <b>2010</b> , 9, 2497-507	7.6	51
71	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. <i>BMJ, The</i> , <b>2010</b> , 341, c4521	5.9	153

70	PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population. <i>Scandinavian Journal of Urology and Nephrology</i> , <b>2010</b> , 44, 378-83		12
69	Male infertility and prostate cancer risk: a nested case-control study. <i>Cancer Causes and Control</i> , <b>2010</b> , 21, 1635-43	2.8	30
68	Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. <i>European Urology</i> , <b>2010</b> , 57, 735-46	10.2	90
67	Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer. <i>International Journal of Cancer</i> , <b>2010</b> , 126, 2296-307	7.5	21
66	miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. <i>International Journal of Cancer</i> , <b>2010</b> , 127, 2768-76	7.5	131
65	Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. <i>European Urology</i> , <b>2009</b> , 55, 87-99	10.2	163
64	Functional magnetic resonance imaging in prostate cancer. <i>European Urology</i> , <b>2009</b> , 55, 801-14	10.2	90
63	Insignificant prostate cancer and active surveillance: from definition to clinical implications. <i>European Urology</i> , <b>2009</b> , 55, 1321-30	10.2	120
62	ETS gene fusions in prostate cancer: from discovery to daily clinical practice. <i>European Urology</i> , <b>2009</b> , 56, 275-86	10.2	279
61	Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. <i>European Urology</i> , <b>2009</b> , 56, 594-605	10.2	123
60	Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. <i>BJU International</i> , <b>2009</b> , 103, 1256-69	5.6	52
59	Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. <i>PLoS ONE</i> , <b>2009</b> , 4, e7953	3.7	53
58	The pentraxin serum amyloid P component is found in the male genital tract and attached to spermatozoa. <i>Journal of Developmental and Physical Disabilities</i> , <b>2008</b> , 31, 508-17		9
57	Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. <i>Experimental Cell Research</i> , <b>2008</b> , 314, 914-26	4.2	24
56	Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. <i>Journal of Reproductive Immunology</i> , <b>2008</b> , 79, 37-43	4.2	29
55	ENSAM: Europium Nanoparticles for Signal enhancement of Antibody Microarrays on nanoporous silicon. <i>Journal of Proteome Research</i> , <b>2008</b> , 7, 1308-14	5.6	36
54	The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. <i>Journal of Interferon and Cytokine Research</i> , <b>2008</b> , 28, 191-6	3.5	35
53	Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 1022-36	9.7	66

52	Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. <i>International Journal of Cancer</i> , <b>2008</b> , 122, 1521-9	7.5	120
51	Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3. <i>Prostate</i> , <b>2008</b> , 68, 269-80	4.2	62
50	FGF-8 is involved in bone metastasis of prostate cancer. <i>International Journal of Cancer</i> , <b>2008</b> , 123, 22-317.5		68
49	Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. <i>European Urology</i> , <b>2007</b> , 52, 1670-9	10.2	64
48	A prospective study on dietary fat and incidence of prostate cancer (MalmöSweden). <i>Cancer Causes and Control</i> , <b>2007</b> , 18, 1107-21	2.8	64
47	The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. <i>International Journal of Colorectal Disease</i> , <b>2007</b> , 22, 1421-7	3	56
46	Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. <i>European Urology</i> , <b>2006</b> , 49, 758-9	10.2	9
45	Topical steroids do not downregulate expression of growth-related oncogene-alpha in nasal polyps. <i>Acta Oto-Laryngologica</i> , <b>2006</b> , 126, 375-80	1.6	4
44	Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. <i>Prostate</i> , <b>2006</b> , 66, 591-603	4.2	41
43	Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation. <i>BJU International</i> , <b>2006</b> , 98, 189-96	5.6	21
42	beta-Microseminoprotein binds CRISP-3 in human seminal plasma. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 333, 555-61	3.4	55
41	Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue. <i>American Journal of Pathology</i> , <b>2005</b> , 167, 1119-24	5.8	27
40	Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract. <i>Journal of Andrology</i> , <b>2005</b> , 26, 333-42		62
39	A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer. <i>Oncogene</i> , <b>2005</b> , 24, 6385-93	9.2	49
38	Lipopolysaccharide-binding protein is produced in the epididymis and associated with spermatozoa and prostasomes. <i>Journal of Reproductive Immunology</i> , <b>2005</b> , 66, 33-43	4.2	28
37	Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 290-7	7.5	49
36	Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. <i>Prostate</i> , <b>2005</b> , 63, 324-9	4.2	40
35	Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. <i>Prostate</i> , <b>2005</b> , 64, 29-39	4.2	27



34	PROQR: a tool for quality control, epidemiological surveillance, patient follow-up and clinical research activities related to prostate cancer. <i>Acta Oncologica</i> , <b>2005</b> , 44, 628-32	3.2	2
33	Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 520-8	12.9	88
32	Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma. <i>Journal of Leukocyte Biology</i> , <b>2004</b> , 76, 685-91	6.5	33
31	Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors. <i>International Journal of Cancer</i> , <b>2004</b> , 108, 654-64	7.5	51
30	Cystatin C is highly expressed in the human male reproductive system. <i>Journal of Andrology</i> , <b>2004</b> , 25, 564-72		30
29	Expression and immunolocalisation of neutral endopeptidase in prostate cancer. <i>European Urology</i> , <b>2003</b> , 44, 415-22	10.2	13
28	Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. <i>Prostate</i> , <b>2003</b> , 57, 196-204	20.4	28
27	Expression and production of the CXC chemokine growth-related oncogene-alpha by human eosinophils. <i>Journal of Immunology</i> , <b>2003</b> , 170, 5309-16	5.3	27
26	Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. <i>Prostate</i> , <b>2002</b> , 53, 50-9	4.2	50
25	Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. <i>Molecular Human Reproduction</i> , <b>2002</b> , 8, 805-10	4.4	76
24	Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 2053-63	5.8	23
23	Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2002</b> , 7, 91-8	2.8	56
22	Semiquantitative morphology of human prostatic development and regional distribution of prostatic neuroendocrine cells. <i>Prostate</i> , <b>2001</b> , 46, 108-15	4.2	27
21	Lipopolysaccharide-binding protein increases toll-like receptor 4-dependent activation by nontypeable Haemophilus influenzae. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 926-30	7	19
20	Increased presence of cells containing transforming growth factor alpha (TGF-alpha) in ulcerative colitis, both during active inflammation and in remission. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2000</b> , 12, 761-6	2.2	6
19	Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. <i>Luminescence</i> , <b>2000</b> , 15, 389-97	2.5	46
18	The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. <i>Infection and Immunity</i> , <b>2000</b> , 68, 4297-302	3.7	179
17	Expression and characterization of trypsinogen produced in the human male genital tract. <i>American Journal of Pathology</i> , <b>2000</b> , 157, 2011-21	5.8	45

16	Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections. <i>Urology</i> , <b>2000</b> , 56, 682-8	1.6	17
15	FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. <i>Oncogene</i> , <b>1999</b> , 18, 2755-61	9.2	121
14	Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections. <i>The Histochemical Journal</i> , <b>1999</b> , 31, 45-52		19
13	Neurogenic origin of human prostate endocrine cells. <i>Urology</i> , <b>1999</b> , 53, 1041-8	1.6	74
12	Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. <i>Urology</i> , <b>1998</b> , 51, 585-9	1.6	120
11	Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. <i>Urology</i> , <b>1994</b> , 43, 427-34	1.6	125
10	Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. <i>Urology</i> , <b>1993</b> , 42, 502-10	1.6	80
9	Human pheochromocytoma cells studied in culture contain large amounts of DSIP-like material. <i>Peptides</i> , <b>1991</b> , 12, 1077-83	3.8	3
8	Immunocytochemical demonstration of DSIP-like immunoreactivity in the hypothalamus of the rat. <i>Peptides</i> , <b>1991</b> , 12, 1155-9	3.8	10
7	Biosynthesis and processing of delta sleep-inducing peptide-like precursors in primary cultures of mouse anterior pituitary cells. <i>FEBS Journal</i> , <b>1990</b> , 190, 131-7		7
6	Amidated joining peptide in the human pituitary, gut, adrenal gland and bronchial carcinoids. Immunocytochemical and immunochemical evidence. <i>Peptides</i> , <b>1990</b> , 11, 149-61	3.8	6
5	Immunoreactive delta sleep-inducing peptide secretion from mouse dissociated, anterior pituitary cells: regulation by corticotropin-releasing factor and arginine vasopressin. <i>Neuroendocrinology</i> , <b>1989</b> , 50, 564-9	5.6	14
4	Gamma 2-MSH immunoreactivity in the human heart. <i>Life Sciences</i> , <b>1989</b> , 45, 787-92	6.8	14
3	Carcinoma of the prostate with Cushing $\beta$ syndrome. <i>European Journal of Endocrinology</i> , <b>1988</b> , 119, 506-516		32
2	Immunoreactive delta sleep-inducing peptide in pituitary adrenocorticotropin/alpha-melanotropin cells and adrenal medullary cells of the pig. <i>Neuroendocrinology</i> , <b>1987</b> , 45, 298-304	5.6	22
1	Delta Sleep-inducing Peptide-like Immunoreactivity in Pituitary ACTH/MSH and Adrenal Medullary Cells. <i>Annals of the New York Academy of Sciences</i> , <b>1987</b> , 512, 476-479	6.5	11